Regulators have permitted Intellia Therapeutics to resume one of two Phase 3 trials of its CRISPR/Cas9 therapy (nexiguran ziclumeran, nex‑z) for transthyretin amyloidosis affecting peripheral nerves (ATTR‑PN), after an earlier clinical hold tied to severe liver events. The companion study in ATTR with cardiomyopathy (ATTR‑CM) remains paused while the FDA continues to investigate a fatality linked to grade‑4 liver transaminase elevations. Intellia said it implemented new safety measures and monitoring to address hepatic risk signals. The agency’s selective clearance points to a path forward for the program but keeps material regulatory uncertainty in place for the broader indication set until the cardiomyopathy trial’s issues are resolved.